Atorvastatin and Rosuvastatin are the most popular representatives of statins, drugs that are well known to people with high blood cholesterol. Despite the fact that they have a similar effect, there are significant differences between them that must be taken into account when choosing a medication.
What do drugs have in common?
To understand what the difference is and which drug is better - Rosuvastatin or Atorvastatin, it is necessary to conduct a comparative analysis. Both drugs under consideration are representatives of the new generation of statins. It is necessary to select one that, along with a noticeable therapeutic effect, has minimal side effects.
Their mechanism of action is approximately the same, but there are slight differences. If you understand the difference between them, you can adjust the treatment of a particular patient, which will significantly improve the prognosis for his recovery. The commonality between Rosuvastatin and Atorvastatin is that both drugs have a dual effect - they reduce the level of bad cholesterol and increase the content of good cholesterol.
Also common to these two drugs is that they:
- improve the condition of the inner lining of blood vessels during its dysfunction;
- improve blood flow through vessels;
- have a beneficial effect on the vascular wall.
Both drugs have common indications for use. Since they belong to the latest generation of statins, they can be prescribed not only for the treatment of diseases, but also for their prevention, which was difficult with the first and second generation statins due to the many side effects from them.
Therefore, the drugs in question are recommended for use in patients who have an increased risk of developing coronary heart disease. Factors that increase this risk include:
- age over 55 years;
- a history of diabetes mellitus;
- addiction to smoking;
- high blood pressure;
- hereditary predisposition to high cholesterol;
- reduced levels of high-density lipoproteins in the blood.
Atorvastatin and Rosuvastatin are not prescribed for the treatment of children and adolescents, during breastfeeding and pregnancy, or in the acute stage of liver disease. They are used with caution if the patient suffers from alcoholism, is predisposed to myopathy, or has a history of renal failure.
The maximum therapeutic effect from taking new generation statins is achieved after 4 weeks from the start of treatment. If the medicine is taken by a woman who has retained reproductive capabilities, then she is recommended to take care of reliable contraception along with statins.
Both drugs have minimal side effects and are therefore well tolerated by patients. They can be taken regardless of food intake and without reference to a specific time of day.
High levels of “bad” cholesterol lead to blockage of blood vessels
Can Atorvastatin be replaced with Rosuvastatin?
In case of poor tolerability of the drug, which is expressed by negative consequences for the liver, confirmed by deterioration of laboratory parameters, it is necessary to adjust the Atorvastatin dosage regimen: temporarily discontinue it, reduce the dosage, or you can replace it with the newest Rosuvastatin.
You cannot do this on your own, because usually 2–4 weeks after stopping the medication, the level of lipids in the blood returns to its original value, which can greatly worsen the patient’s health. Therefore, the decision about the possibility of replacement should be made together with your doctor.
What is the difference
A comparison of the drugs Atorvastatin and Rosuvastatin revealed that, despite some similarities, they belong to statins of different generations. Rosuvastatin is the latest development, and Atorvastatin precedes it. The advantage of the latest generation is that the dosage of the drug can be reduced, since it is highly effective.
Lovastatin and its analogues
Unlike Atorvastatin, 90% of Rosuvastatin is excreted from the body through the digestive system, and 5% through urine. In addition, if we compare drugs with each other in terms of lowering low-density cholesterol, Atorvastatin is slightly inferior to Rosuvastatin.
The first reduces by a maximum of 54%, and the second by 63%. They also differ in their half-life. If for Atorvastatin this period of time takes from 15 to 30 hours, then for Rosuvastatin it takes 19 hours.
The newest generation drug has a higher bioavailability. This means that it is better absorbed by the body. But the difference between them is not so significant: Atorvastatin – 12% and Rosuvastatin – 20%.
What also makes these drugs different is the nature of their solubility. Thus, Rosuvastatin is a hydrophilic drug, and Atorvastatin is lipophilic. This means that Atorvastatin is fat soluble and Rosuvastatin is water soluble. If you have to make a choice between Atoris and Rosuvastatin, then you must keep in mind that Atoris is a type of Atorvastatin, so the similarities and differences will be approximately the same.
In terms of safety, both drugs under consideration are approximately the same. But, for example, in type 2 diabetes, preference should be given to Rosuvastatin, since it has less effect on carbohydrate metabolism.
If we compare these drugs by cost, then in general the price of Atorvastatin is significantly lower than the cost of Rosuvastatin. In this sense, the dosage of the drug and the number of tablets in the package are important. For example, 90 tablets of 20 mg of Atorvastatin will cost about 800 rubles, while for the same package of Rosuvastatin you will have to pay more than 1000 rubles.
Judging by the effectiveness of these drugs, practice shows that Rosuvastatin has a more pronounced effect compared to Atorvastatin. Their effectiveness is higher, and the potential for side effects is lower than that of first-generation statins, for example, Simvastatin.
Why does atorvastatin have advantages on the “restricted” lists?
Comparative effectiveness of statins Today, no one doubts the direct correlation between the level of cholesterol (C) and low-density lipoprotein cholesterol (LDL-C) in the blood and cardiovascular mortality. Therefore, the main goal of lipid-lowering therapy is to reduce LDL cholesterol. Recent meta-analyses show that the most effective drugs for the treatment of severe lipid metabolism disorders are synthetic statins [7] (atorvastatin in a daily dose of 10 mg reduces LDL levels by an average of 39%, lovastatin and pravastatin in a dose of 40 mg - by 31%, simvastatin 40 mg – by 35–41%, fluvastatin 40–80 mg – by 25–35%, rosuvastatin 10 mg – 39–45%) [15]. Obviously, the use of 10 mg of atorvastatin is equivalent to 20 mg of simvastatin, 40 mg of lovastatin and pravastatin, 80 mg of fluvastatin. At these doses, comparable statins [10] reduce the concentration of LDL cholesterol by an average of 34%, and total cholesterol by 27%, while atorvastatin reduces them by 55% (and according to a number of studies, by 61%) and by 46 % respectively. A distinctive feature of atorvastatin is its ability to effectively reduce triglyceride levels by 23–45%, which is comparable to the effect of rosuvastatin. Not only rosuvastatin, but also atorvastatin reduces CRP levels and affects HDL levels. The results of the largest JUPITER study showed that rosuvastatin in the first 12 months. increased HDL content by only 4%. At the same time, atorvastatin has shown high efficiency in a wide range of dosages (from 5 to 80 mg per day), which is extremely important when conducting aggressive lipid-lowering therapy. Comparison of the results of large clinical trials (Fig. 1) allows us to conclude that atorvastatin can most often achieve target lipid levels. Evidence base for the use of statins. As Graham Jackson put it, the world has come close to the threshold of the “great statin war.” As criteria for the preference of a particular statin, as a rule, they appeal either to laboratory and biochemical effectiveness, or to the ability to reduce overall and cardiovascular mortality. Although when prescribing many statins, it is possible to achieve normalization of blood lipid parameters with the correct dosage, a large evidence base has been accumulated according to which atorvastatin is much more effective than simvastatin and rozyvastatin in reducing cardiovascular complications. Based on the results of large multicenter randomized studies (CARE and WOSCOPS - pravastatin, 4S - simvastatin), they state a reduction in the risk of coronary mortality by 20–42%, the incidence of myocardial infarction by 25–37%, and the incidence of stroke by 28–31% . However, it should be noted that the dosage regimen and initial cholesterol level in these studies were fundamentally different (in the CARE and WOSCOPS studies, pravastatin [18] was prescribed to patients with a total blood cholesterol level of 4.0–6.2 mmol/l at a dose of 40 mg per day, and in the 4S study [14], simvastatin was prescribed for hypercholesterolemia of 5.5–8.0 mmol/l and a daily dose of 20–40 mg). It seems that this approach of indirectly comparing the effectiveness of drugs does not comply with the principles of evidence-based medicine. And besides this, data on the effect of statins on other clinically important surrogate points and other pathologies concomitant with hyperlipidemia are ignored. If we compare the results of the GREACE [1] and 4S studies, it turns out that atorvastatin reduces overall mortality, mortality from coronary artery disease, and the number of heart attacks and strokes almost 2 times more significantly than simvastatin (Fig. 2). Moreover, a clear advantage of atorvastatin over simvastatin in terms of the rate of reduction in the risk of developing cardiovascular complications is revealed: atorvastatin reduces the risk of their development after just three months of taking the drug, and simvastatin only after 1.5 years. Without going into a discussion about the advisability of using higher doses of statins from the very beginning of treatment with them, it is important to keep in mind the results of the GREACE study [1], in which the initial dose of atorvastatin was 20 mg per day (average dose 24 mg per day). 95% of patients on this dose of atorvastatin achieved target LDL cholesterol levels, while only 3% of patients in the usual care group did so. Of particular interest to clinicians is the ability of statins not only to prevent or slow the development, but also to reduce the size of existing atherosclerotic plaque. Atorvastatin has been shown to slow down and regress atherosclerotic plaque in at least two large studies using intravascular ultrasound, REVERSAL [11] and ESTABLISH [13]. It is very interesting to compare the results of the ESTABLISH (atorvastatin) and ASTEROID (rosuvastatin) studies [12]. 6-month therapy with atorvastatin at a dose of 20 mg per day led to a decrease in atheroma size by 13.1%, while 24-month therapy with rosuvastatin at a dose of 40 mg per day was accompanied by a decrease in atheroma size by 6.8%. Noteworthy is the fact that the average therapeutic dose of atorvastatin in terms of severity and rate of reduction of atheroma looked at least no worse than a high dose of rosuvastatin. If we analyze the number of studies on statins (www.medlinks.ru/aticle.php?sid=10855) with “hard” endpoints (overall mortality, cardiovascular mortality, myocardial infarction, stroke) and the number of patients included in them, then atorvastatin leads in the number of works, along with simvastatin and pravastatin, despite the fact that it appeared on the market much later than them. So, we can conclude that atorvastatin allows not only to achieve a pronounced and persistent reduction in atherogenic lipid fractions and improve the lipid profile in general, significantly slowing the progression of atherosclerosis, but also, most importantly, it has been proven to reduce the risk of developing cardiovascular disease. At the same time, it is atorvastatin that most closely corresponds to the principle of treating atherosclerosis: we treat not high cholesterol, but a patient with a high risk of developing cardiovascular complications. Clinically significant interactions between statins and other drugs Since the advent of statins, the issue of possible positive synergistic effects on endpoints when combined with antihypertensive drugs has been actively discussed. Disappointment after the publication of the results of the ALLHAT-LLA substudy (pravastatin was added to antihypertensive therapy) was dispelled only after the completion of the ASCOT-LLA trial [16,17]. In the ASCOT-LLA study, during therapy with amlodipine + perindopril, a reduction in the incidence of the primary endpoint by 36%, as well as secondary endpoints (fatal and non-fatal stroke - by 27%, all cardiovascular events and procedures - by 21%, of all coronary events – by 29%). At the same time, in the group of patients who received the treatment regimen amlodipine + perindopril + atorvastatin, the relative risk of reducing the development of non-fatal myocardial infarction and fatal ischemic heart disease was 48%, and fatal and non-fatal stroke was 44%. Apparently, it is the combination of amlodipine and atorvastatin that is most optimal for realizing a synergistic interaction [2]. One study showed that it is the combination of amlodipine and atorvastatin that best ensures not only the achievement of target lipid levels, but also blood pressure [3,8]. There are several explanations for this fact. First of all, amlodipine and atorvastatin are the undoubted leaders in their drug classes. In addition, the combination of amlodipine + atorvastatin has a beneficial effect on interleukin (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity (IR). It was shown that y 50 patients with normal cholesterol levels (total cholesterol <5.2 mmol/l], body mass index >/=30 kg/m2 and increased DBP >90 and <105 mmHg and SBP >140 and <180 mmHg) in a cross-over design after 12 weeks there are significant differences between the two compared treatment regimens (amlodipine 10 mg and amlodipine 10 mg + atorvastatin 20 mg). During monotherapy with amlodipine, there was a decrease in SBP and DBP (by 17.1 and 14.3 mm Hg, respectively, p = 0.008), TNF-alpha (from 3.66 ± 1.6 to 3.09 ± 1, 1 pkg/ml, p=0.045) and IR (from 4.58±0.7 to 3.88±0.6, p=0.007). When using the combination of amlodipine + atorvastatin, a decrease in SBP and DBP was detected (by 22.5 and 17.7 mm Hg, respectively; p = 0.04 when compared with amlodipine monotherapy), TNF-alpha (by 2.59 ± 0 .9 pkg/ml; p=0.038 when compared with amlodipine, IR (by 2.86±0.4; p=0.007 when compared with amlodipine), IL-6 (from 7.93±1.9 to 5.59±1 .2 pkg/ml; p=0.007 compared with amlodipine) and total cholesterol (from 4.3±0.5 to 3.6±0.4 mmol/l; p=0.008 compared with amlodipine).It is obvious that the combination of amlodipine + atorvastatin not only has a more pronounced antihypertensive effect, but also significantly reduces the manifestations of insulin resistance and inflammation [5].Many authors believe that there is a possible interaction between amlodipine and statins at the molecular level, which leads to the stabilization of the atherosclerotic plaque and causes a more pronounced reducing the risk of coronary events [3,8] Pharmacoeconomics of statins The effectiveness/cost ratio of lipid-lowering therapy is of great practical interest. The large-scale CURVES study showed that the high effectiveness of atorvastatin in influencing LDL cholesterol levels determines its better pharmacoeconomic indicators compared to other statins. It is fundamentally important to emphasize that all of the above, from lowering lipid levels to stabilization and regression of atherosclerotic plaque, concerned exclusively the original atorvastatin - Liprimar (), and it is impossible to automatically extrapolate these data to the numerous generics of atorvastatin existing in Russia. Of course, there are high-quality drugs among them, but they must prove their clinical and therapeutic effectiveness (at least in terms of their effect on the main, surrogate points) in direct comparative studies. As confirmation of the above about the advantages of Liprimar, we can cite the results of an analysis of 80 thousand patients from the Real World database on reducing the risk of developing cardiovascular complications in comparison with simvastatin. A retrospective Buena Vista analysis of a large US database found that patients treated with Liprimar (atorvastatin calcium) had a 14% lower risk of cardiovascular events, including myocardial infarction and stroke, compared with patients treated with simvastatin even after dose adjustment. The analysis included 61,324 patients taking Liprimar and 19,585 taking simvastatin who had not received a statin in the 6 months before the start of the study. The primary endpoint was defined as hospitalization due to myocardial infarction, stroke, mini-stroke (transient ischemic attack), chest pain (angina) or coronary heart disease, vascular disease or other conditions requiring cardiac surgery, and was assessed after taking a statin for at least 3 months of therapy. In an analysis that took into account the reduction in the risk of cardiovascular events, starting from the first day of treatment with Liprimar, compared with the simvastatin group, there was a 26% lower risk reduction. Differences in the clinical effect in patients taking Liprimar or simvastatin were evident within the first 3 months and increased accordingly during the further observation period. Interestingly, an earlier similar study in the Netherlands involving 3,500 patients and based on data from general practitioners showed that patients receiving Liprimar had a 30% greater reduction in the risk of cardiovascular events than those receiving other statins ( simvastatin, pravastatin, fluvastatin and cerivastatin). Thus, today atorvastatin (Liprimar) is the only statin that combines a reduction in LDL levels from 39 to 60% and an evidence base in the form of more than 400 ongoing and completed clinical studies involving more than 80 thousand patients (of which more than 50 thousand patients took participation in more than 10 endpoint studies focused on reducing the risk of cardiovascular events).
References 1. Athyros V, Papageorgiou A, Mercouris B. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREACE study. Current Medical Research and Opinion; 2002; 18, 4: 220–228 2. Blank RA single–pill combination of amlodipine besylate and atorvastatin calcium. Drugs Today (Barc). 2006; 42(3):157–75. 3. Dorval JF, Anderson T, Buithieu J, Chan S. et al. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiol. 2005; 95(2):249–53. 4. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts). Eur Heart J 2003; 24: 1601–10 5. Fogari R, Preti P, Zoppi A, Lazzari P, Corradi L, Fogari E, Ciccarelli L, Derosa G. Effects of amlodipine–atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 2006; 6: 178–81. 6. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457–81 7. Istvan E. Statin inhibition of HMG–CoA reductase: a 3-dimensional view Atherosclerosis 2003;Suppl. 4:3–8 8. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opinion on Pharmacotherapy. 2004; 5:459–468. 9. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–60. 10. Moghadasian MH, Mancini & Frohlich. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. // Exp.Opin.Pharmakother.(2000) 1(4), p.683–695 11. Nissen S, Tuzcu M, Schoenhagen P. Effect of Intensive Compared With Moderate Lipid–Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA. 2004;291:1071–1080 12. Nissen S, Nicholls S, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA. 2006;295:1556–1565 13. Okazaki S, Yokoyama T, Miyauchi K Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation. 2004;110:1061–1068. 14. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383–9 15. Schaefer EJ, McNamara JR, Tayler T et al., Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary disease heart disease versus control subjects. Am J Cardiol. 2004;93(1):31–9 16. Sever P on behalf of the ASCOT investigators. ASCOT–LLA revisited: Interaction of antihypertensive and lipid–lowering therapy. American Heart Association Scientific Sessions; November 14, 2005; Dallas, TX. 17. Sever PS, Dahlof B, Poulter NP, Wedel H. Anglo–Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT LLA) revisited: interaction of antihypertensive and lipid lowering therapy. Circulation 2005; 112 (17 Suppl.): II–134. Abstract 730. 18. West of Scotland Coronary Prevention Study: implications for clinical practice. The WOSCOPS Study Group. Eur Heart J 1996 Feb;17(2):163–4
Features of Atorvastatin
The drug Atorvastatin belongs to the category of third generation statins. The drug is available in various dosages - 10, 20, 40 and 80 mg. The pharmacy chain offers 2 types of this drug - Russian (Atorvastatin) and Israeli (Atorvastatin-Teva). The active ingredient in Atorvastatin is atorvastatin calcium trihydrate.
The drug reduces the concentration of low-density lipoproteins and simultaneously increases the content of high-density lipoproteins. Also effective for familial and homozygous hypercholesterolemia. The effectiveness of the medicine appears after 2 weeks of regular use. After just 30 days, the maximum effect of the anticholesterol drug is achieved, which persists throughout the entire duration of treatment.
Atorvastatin, like Rosuvastatin, belongs to a new generation of statins
Taking Atorvastatin must be combined with diet. According to the diet, the patient must exclude from the diet foods rich in animal fats, as well as dishes prepared by frying. You can take the tablets regardless of meal time. The dosage is selected individually by the attending physician based on the results of the lipid profile.
The initial dosage is 10 mg; subsequently, if necessary, it can be increased to 80 mg per day. Patients suffering from renal or liver failure take Atorvastatin at this initial dosage all the time. Indications for the use of Atorvastatin are the complex treatment of high levels of total cholesterol and LDL and increased levels of triglycerides.
The following side effects may occur while taking Atorvastatin:
- sleep disturbance;
- headache and dizziness;
- anemia or thrombocytopenia;
- dyspeptic disorders;
- arthritis and myalgia;
- allergy;
- swelling;
- baldness;
- increased sweating;
- sensitivity to light.
Atorvastatin is not prescribed for use in cases of increased activity of liver enzymes, renal failure, during pregnancy and lactation, in case of individual intolerance to the components of the drug, severe liver pathologies. The drug is also contraindicated in patients under 18 years of age.
The cost of the drug in pharmacies depends on the dosage and manufacturer and varies from 130 to 400 rubles. Its analogues are the drugs Atoris, Liprimar, Tulip.
Comparison of the safety of Rosuvastatin and Rozart
The safety of a drug includes many factors.
Moreover, with Rozart it is higher than with Rosuvastatin. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in Rosart, as well as in Rosuvastatin, we look at which organ is the metabolizing organ and how critical the effect on it is.
The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Rozart has fewer risks when used than Rosuvastatin.
Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Rozart and Rosuvastatin.
Features of Rosuvastatin
Rosuvastatin is a lipid-lowering agent and is prescribed to normalize the level of triglycerides and phospholipids and lipoproteins in the blood. The main active ingredient is rosuvastatin. It is prescribed for the treatment and prevention of hypercholesterolemia, atherosclerosis and its complications, and vein thrombosis.
Rosuvastatin reduces high concentrations of low-density cholesterol, total cholesterol, triglycerides, and apoliprotein. At the same time, it helps to increase the level of high-density lipoproteins. While taking this drug, the atherogenicity index decreases. This effect indicates normalization of the lipid profile.
Indications for prescribing this drug are as follows:
- hereditary tendency to increase cholesterol;
- initial detection of high cholesterol levels in the blood;
- increased levels of triglycerides in the blood;
- prevention of complications of atherosclerosis, namely angina pectoris, hypertension, myocardial infarction and stroke in patients over 50 years of age.
Since Rosuvastatin is not metabolized in the liver, its effect on this organ is minimal. After 90% of the drug is excreted through the intestines with feces, the rest through the kidneys with urine. The drug is not prescribed to persons under 18 years of age, patients with lactose intolerance, women during pregnancy and breastfeeding.
It is contraindicated in patients at the acute stage of liver disease, patients with myopathy, and those with individual intolerance to the components of the drug. The combination of Rosuvastatin with Cyclosporine is unacceptable. During treatment with this statin, doctors recommend following an anti-cholesterol diet. When prescribing a drug in a dosage of more than 40 mg, the attending physician takes into account the absolute and relative indications for this.
Rosuvastatin lowers cholesterol levels better than all other similar drugs
Both drugs - Atorvastatin and Rosuvastatin - have good patient reviews. Since these medications have similar effects, they are interchangeable. But the choice of a particular one should be determined by the doctor in accordance with the diagnosis and individual characteristics.
Comparison of addiction between Rosuvastatin and Rozart
Like safety, addiction also involves many factors that must be considered when evaluating a drug.
So, the totality of the values of such parameters as “syndrome o” in Rosuvastatin is quite similar to the similar values in Rozart. Withdrawal syndrome is a pathological condition that occurs after the cessation of intake of addictive or dependent substances into the body. And resistance is understood as initial immunity to a drug; in this it differs from addiction, when immunity to a drug develops over a certain period of time. The presence of resistance can only be stated if an attempt has been made to increase the dose of the drug to the maximum possible. At the same time, Rosuvastatin has a fairly low “syndrome” value, just like Rozart.
Reviews
Oksana, 46 years old, Pyatigorsk: I took Atorvastatin to lower cholesterol. It reduces well, but I experienced side effects myself. After 3 months of regular use, almost all lipid profile indicators, except triglycerides, approached normal. Based on the results of the analysis, the doctor supplemented the treatment with Dibikor, and triglycerides also decreased. I was afraid for my liver, but in vain. Everything is fine there.
Ekaterina, 35 years old, Moscow: I can’t say that Atorvastatin is significantly different in effectiveness from previous drugs. My father was prescribed 60 mg per day; he has high cholesterol. He says that he does not notice any significant changes in his condition after the course of treatment. Cholesterol remains what it was. Apparently this is due to hereditary predisposition.
Kirill, 60 years old, Samara: With a diagnosis of coronary heart disease, the doctor prescribed statins to prevent complications. The choice fell on the drug Rosuvastatin. I don’t feel its influence on myself, but according to tests, cholesterol corresponds to the norm for a healthy person. Before starting to take Rosuvastatin, it was increased several times. I can confidently recommend this drug to others to reduce high cholesterol.
Comparison of ease of use of Rosuvastatin and Rozart
This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.
The ease of use of Rosuvastatin is approximately the same as Rozart. However, they are not convenient enough to use.
The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.
Last update date: 2021-01-10 10:02:28
